WSJ Pro Private Equity

Private-Equity Firms Plow Record Amounts Into Biopharmaceutical Sector

Private-Equity Firms Plow Record Amounts Into Biopharmaceutical Sector

Large deals in the biopharma space are driving more activity in the sector while industry veterans continue to specialize

  • marzo 08, 2020
  • Tempo di lettura min.

WSJ Pro Private Equity

Private-Equity Firms Plow Record Amounts Into Biopharmaceutical Sector

Health care-focused private-equity firms bet big on biopharmaceutical deals in 2019, despite the regulatory scrutiny the sector has faced in recent years.

“Private equity has long been interested and invested in the ‘picks and shovels’ that fuel the biopharma industry, such as clinical research services, pharma IT and life science tools,” said Nirad Jain, a partner with Bain & Company who co-leads the firm's global health-care private-equity and corporate mergers-and-acquisitions practice.

He added that there has been an increased interest from private equity in biopharmaceutical products, services and health-care information technology supporting research-and-development and commercialization efforts.

Vedi di più su WSJ Pro Private Equity